In addition, BioServe-Europe is also expected to distribute biospecimens from its Global BioRepository and biobank partner network, as well as samples sourced from within the EU.
Working with BioServe-Europe, many European scientists will for the first time have access to a single source of biosamples covering most major diseases and comprehensive analytical services to unlock and correlate sample information for their research.
The complementary services are crucial to furthering the understanding of disease and the development of new research discoveries and therapies.
Rama Modali, president of BioServe, said: “The combination of cutting edge genomic services and high-quality biosamples has proven to be a powerful offering for the scientific community in North America. Our recent foray in the EU market, working with NGC Medical, has revealed a similar strong demand for these unique services.
“The EU market is also quickly adopting new in-vitro diagnostic tests as part of a move to a personalized medicine regime. BioServe-Europe’s genomic services have the ability to a key component in the processing and validation of these tests’ results.”
Paolo Cremascoli, President and CEO of NGC Medical SpA, said, “Our experience working with BioServe has been overwhelmingly positive. From our vantage point it is clear that offering BioServe’s complement of services in Europe will continue to be well received. There is simply a lack of high-quality genomic validation services and tissue samples to support the European research market.”
In April of this year, BioServe began its collaboration with NGC Medical, providing them with CLIA-certified personalized genomics services, including DNA extraction, QC DNA, and control DNA for NutriGeneCode validation.
NutriGeneCode is a simple, non-invasive saliva test able to identify 50 of the most significant Single Nucleotide Mutations (SNPs) involved in cellular aging and consequent body response, such as lipid and carbohydrate metabolism, hypertension, inflammation, oxidation and detoxification reactions and DNA repair.
NGC Medical manufactures and distributes medical devices and designs and builds operating rooms, intensive care units and catheterization laboratories.
BioServe provides a ‘biomaterial to validated data’ genomics services platform, helping researchers gain the pre-clinical data for breakthroughs in drug discovery, molecular diagnostics and pharmacogenomics.
Utilizing BioServe’s genomics services platform, researchers can identify genetic markers, validate drug targets and correlate clinical data with molecular data to accelerate the development of new and safer drugs.
BioServe’s services extend from nucleic acids processing, DNA synthesis, high throughput sequencing and genotyping, genome wide-scans and gene expression analyses to ready-made large epidemiologically sound case-control studies of inflammatory disorders, endocrine disorders, cardiovascular disease, diabetes, hypertension, obesity and many cancers.
